CliffBio
small molecule

DORYX

DOXYCYCLINE HYCLATE

Loss of exclusivityFebruary 2028latest FDA-listed patent expiry
CompanyMAYNE PHARMA INTERNATIONAL PTY LTD

Drug detail

Brand nameDORYX
Active ingredientDOXYCYCLINE HYCLATE
StrengthEQ 80MG BASE
Dosage formTABLET, DELAYED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalApril 2013
Marketing statusDISCN

Listed patents

PatentExpiresType
8715724February 2028product

More from MAYNE PHARMA INTERNATIONAL PTY LTD

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

DORYX patent cliff — loss of exclusivity February 2028 | CliffBio